EU orphan medicines regulation failed
July 29, 2020
Two decades of EU market protection of ‘orphan’ (rare disease) medicines have greatly benefitted the industry. According to research by The Investigative Desk, published in
Daan Marselis
Daan Marselis (1983) has been working as a freelance journalist since the autumn of 2010. His work was published by the Dutch Journal of Medicine (‘Nederlands Tijdschrift voor Geneeskunde’), Trouw, de Volkskrant, de Correspondent, CNN, Vrij Nederland and several professional journals for health care executives. Marselis is currently working as a producer for Dutch radio station BNR Nieuwsradio. In December 2018, he joined The Investigative Desk, where he specialises in researching and writing about the pharmaceutical and health care industries.
Publications:
EMA rewrites medicine approval policy
May 26, 2020
New innovative medicines should be made available to European citizens more quickly. That is why the European Medicines Agency updates the process for market authorisation.
